We are at a critical point in human history. We now have the tools to dramatically reduce or eliminate the risk of future epidemics and pandemics. Achieving such a goal will take a coordinated and collective global response, and CEPI’s contributions will be central to this long-term global effort.
We must invest now in the vaccines and biologic countermeasures that we need, while linking these investments with commitments to equitable access. The $3.5 billion CEPI needs to implement our five-year strategy represents a critical down payment towards the goal of a world safe from the devastating effects of epidemic and pandemic diseases.Dr Richard Hatchett, CEO, CEPI
How CEPI will allocate the US$3.5 billion to tackle future pandemics and epidemics
CEPI will allocate the US$3.5bn to prepare for known epidemic and pandemic threats, transform the response to the next novel threat, and connect and enhance global collaboration to strengthen global preparedness. CEPI will work to substantially reduce global epidemic and pandemic risk by:
1.Strengthening our defenses against COVID-19 and reducing the risk of future coronavirus pandemics, by optimizing our current vaccines, addressing variants of concern, developing next-generation COVID-19 vaccines, and initiating the development of broadly protective or universal coronavirus vaccines.
2.Developing vaccines for known threats, to include completing the development of vaccines for Chikungunya, Lassa Fever, Nipah, and MERS, advancing the development of vaccines against Rift Valley Fever, and completing additional clinical trials to broaden the populations eligible for the Ebola vaccines.
3.Working to compress vaccine development timelines to 100 days by optimizing the capabilities of rapid response platforms including mRNA, preparing clinical trial networks to respond rapidly to new threats, working closely with global regulators to streamline regulatory requirements, and linking manufacturing facilities to enable rapid production of pandemic vaccines.
4.Producing a library of prototype vaccines and other biological interventions against representative pathogens from critical viral families. The “library of prototype vaccines” will be developed through phase 1 clinical trials and use rapid response platforms that will allow rapid adaptation if related viruses emerge.
5. Establishing global networks for lab capacity, assays, and preclinical models that are critical for rapid vaccine development and developing arrangements with existing national or regional clinical trial and manufacturing networks.
6. Supporting the efforts of low- and middle-income countries to take full ownership of their national health security by developing the infrastructure and expertise to conduct epidemiological and clinical studies, support technology transfer, and establish national and regional vaccine manufacturing.
Notes to the editor
CEPI’s $3.5 billion investment case – The Urgency of Now. Turning the tide against epidemic and pandemic infectious diseases
The full investment case may be accessed at endpandemics.cepi.net.
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines to stop future epidemics. CEPI has moved with great urgency and in coordination with WHO in response to the emergence of COVID-19. CEPI has initiated 11 partnerships to develop vaccines against the novel coronavirus. The programmes are leveraging rapid response platforms already supported by CEPI as well as new partnerships.
Before the emergence of COVID-19, CEPI’s priority diseases included Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also invested in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (Disease X).
CEPI’s founders and initial investors are the governments of Norway, Germany, Japan, India, the World Economic Forum, the Bill & Melinda Gates Foundation and Wellcome.
A full list of CEPI’s financial supporters can be found here.
For more information, please contact:
CEPI Press Office
+44 7387 055214